Windlas Biotech Limited

BSE: 543329 NSE: WINDLAS
Windlas Biotech Limited - pharma in Dehradun, Uttarakhand, India. FY 2026 financials and compliance.
CIN L74899UR2001PLC033407 Incorporated 19 February 2001 ROC Uttarakhand HQ Dehradun, Uttarakhand, India
Active Listed - NSE: WINDLAS · BSE: 543329 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹904.09 Cr
▲ 18.98% YoY
Computed EBITDA · FY 2026
₹122.55 Cr
▲ 9.29% YoY
Net profit · FY 2026
₹66.46 Cr
▲ 8.95% YoY
Authorised capital
₹77.5 Cr
Registered with MCA
Paid-up capital
₹10.55 Cr
Issued & subscribed
Open charges
₹73.3 Cr
Satisfied ₹183.4 Cr
Company age
25 yrs
Est. 2001
Employees · EPFO
1,153
Latest available

About Windlas Biotech Limited

Data last updated: 14 July 2026

Windlas Biotech Limited is a public limited company based in Dehradun, Uttarakhand, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 19 February 2001, the company has been in operation for over 25 years.

Registered with ROC Uttarakhand under CIN L74899UR2001PLC033407. Listed on BSE: 543329 and NSE: WINDLAS.

Capital: an authorised share capital of ₹77.5 Cr and a paid-up capital of ₹10.55 Cr. Formerly known as Windlas Biotech Private Limited. It is led by directors including Pawan Kumar Sharma and Prachi Jain Windlass.

Last AGM: 28 July 2025. Financial statements filed for year ended 31 March 2025. Office: 40/1 Mohabewala Industrial Area, Dehradun, Uttarakhand, India – 248110.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹904.09 Cr, a growth of 18.98% compared to the previous year. The net worth stands at ₹580.84 Cr (up 14.84% YoY). Total assets are valued at ₹907.35 Cr (up 19.32% YoY).

The company has a workforce of approximately 1,153 employees as per the latest available data.

The company is associated with 1 brand - Windlas. As per MCA filings, the company has open charges of ₹73.3 Cr and satisfied charges of ₹183.4 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website windlas.com.

Company Details of Windlas Biotech Limited
CIN L74899UR2001PLC033407
Registration Number 033407
Incorporation Date 19 February 2001
ROC Uttarakhand
Listing Status Listed (BSE: 543329, NSE: WINDLAS)
Company Status Active
Date of Last AGM 28 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Hitesh Windlass Managing Director Manoj Kumar Windlass Managing Director Pawan Kumar Sharma Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    windlas.com
  • Social Media
  • Registered Address
    40/1 Mohabewala Industrial Area, Dehradun, Uttarakhand, India – 248110
  • Industry
    Pharma, Drug Formulation & Development
Company report
Windlas Biotech Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Windlas Biotech Limited report

Financials, compliance, directors, charges, ownership and filings for Windlas Biotech Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Windlas Biotech Limited

Windlas Biotech Limited has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74899UR2001PLC033407, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L74899UR2001PLC033407 Current
U74899UR2001PLC033407 Previous
U74899DL2001PLC109721 Previous
U74899UR2001PTC033407 Previous

Associated Brands with Windlas Biotech Limited

Windlas Biotech Limited operates one associated brand: Windlas. These brands represent Windlas Biotech Limited's diversified market presence and brand portfolio.

Brand Description Website
Windlas
Biopharma regulatory affairs, quality control, and strategy services are provided. windlas.com

Competitors & Alternatives of Windlas Biotech Limited

Brands and companies operating in the same space as Windlas Biotech Limited include Jubilant Life Sciences, Akums, Nectar Lifesciences and 4 more.

Competitor Description Location Founded
Jubilant Life Sciences Jubilant Life Sciences Company offering a suite of R&D and manufacturing services for small molecules and generics Noida, India, India 1978
Akums Akums CDMO focusing on spectrum of dosage forms and therapeutic segments Delhi, India, India 2004
Nectar Lifesciences Nectar Lifesciences Cephalosporin APIs and generic formulations are manufactured. Chandigarh, India, India 1995
Unither Unither Contract development and manufacturing organization for proprietary and generic drugs Paris, France, France 1993
Recipharm Recipharm Pharmaceutical development and manufacturing services are offered contractually. Jordbro, Sweden, Sweden 1995
CoreRx CoreRx CDMO with a focus on early phase drug product development Clearwater, United States, United States 2006
MedPharm MedPharm Topical and inhaled drug delivery formulations are developed and manufactured. Guildford, United Kingdom, United Kingdom 1998

Business Activity of Windlas Biotech Limited

Windlas Biotech Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Windlas Biotech Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Windlas Biotech Limited

Windlas Biotech Limited is audited by SS KOTHARI METHA & COMPANY LLP for the financial year 2025. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
SS KOTHARI METHA & COMPANY LLP Locked Locked Locked
Premium access

Complete auditor history for Windlas Biotech Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Windlas Biotech Limited

Windlas Biotech Limited is currently managed by 8 directors, with 12 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Pawan Kumar Sharma
Also directs: Windlas Biotech Limited
Whole-Time Director 11 Jun 2019 7 Years 2 Months Current
Prachi Jain Windlass
Also directs: Windlas Biotech Limited, Michael & Susan Dell Foundation India Llp
Director 03 May 2021 5 Years 3 Months Current
Vivek Dhariwal
Also directs: Windlas Biotech Limited
Director 06 May 2021 5 Years 3 Months Current
Gaurav Gulati
Also directs: Windlas Biotech Limited, Aroa Innovation Partners Llp, Redsprig Innovation Partners Llp and 5 more
Director 06 May 2021 5 Years 3 Months Current
Hitesh Windlass
Also directs: Windlas Biotech Limited
Managing Director 21 Jan 2008 18 Years 6 Months Current
Manoj Kumar Windlass
Also directs: Windlas Biotech Limited, Windlas Exports Private Limited
Managing Director 01 Apr 2006 20 Years 4 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Windlas Biotech Limited FY 2026 filings available

Windlas Biotech Limited reported revenue of ₹904.09 Cr (up 18.98% YoY) for FY 2026.

Revenue · FY 2026
₹904.09 Cr ▲ 18.98%
Profit · FY 2026
₹66.46 Cr ▲ 8.95%
Computed EBITDA · FY 2026
₹122.55 Cr ▲ 9.29%
Revenue₹ Cr · Consolidated05001,000FY 2022: ₹466 Cr466FY 2022FY 2023: ₹513 Cr · +10.1% YoY513+10.1%FY 2023FY 2024: ₹631 Cr · +23% YoY631+23%FY 2024FY 2025: ₹760 Cr · +20.4% YoY760+20.4%FY 2025FY 2026: ₹904 Cr · +19% YoY904+19%FY 2026
Net Profit₹ Cr · Consolidated0255075FY 2022: ₹38 Cr38.1FY 2022FY 2023: ₹43 Cr · +11.9% YoY42.6+11.9%FY 2023FY 2024: ₹58 Cr · +36.5% YoY58.2+36.5%FY 2024FY 2025: ₹61 Cr · +4.8% YoY61+4.8%FY 2025FY 2026: ₹66 Cr · +9% YoY66.5+9%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0100200300Q1'25: ₹175 Cr · +21% YoY175+21%Q1'25Q2'25: ₹187 Cr · +22.5% YoY187+22.5%Q2'25Q3'25: ₹195 Cr · +20.2% YoY195+20.2%Q3'25Q4'25: ₹203 Cr · +18.3% YoY203+18.3%Q4'25Q1'26: ₹210 Cr · +19.9% YoY210+19.9%Q1'26Q2'26: ₹222 Cr · +18.9% YoY222+18.9%Q2'26Q3'26: ₹233 Cr · +19.5% YoY233+19.5%Q3'26Q4'26: ₹238 Cr · +17.7% YoY238+17.7%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Revenue from Operations ₹904.09 Cr ₹759.88 Cr ₹630.96 Cr ₹513.08 Cr ₹465.93 Cr
Other Income ₹17.8 Cr ₹18.02 Cr ₹13.47 Cr ₹9.97 Cr ₹6.71 Cr
Total Income ₹921.89 Cr ₹777.9 Cr ₹644.42 Cr ₹523.05 Cr ₹472.64 Cr
Cost of Materials Consumed ₹12.46 Cr ₹2.33 Cr ₹2.96 Cr -₹76.2 Lakh ₹307.56 Cr
Purchases of Stock-in-Trade ₹537.67 Cr ₹491.05 Cr ₹383.63 Cr ₹341.48 Cr ₹0
Changes in Inventories ₹7.1 Cr -₹21.52 Cr ₹9.59 Cr -₹15.27 Cr -₹4.74 Cr
Employee Benefit Expense ₹152.09 Cr ₹122.92 Cr ₹87.46 Cr ₹70.32 Cr ₹63.41 Cr
Finance Costs ₹4.83 Cr ₹4.38 Cr ₹1.11 Cr ₹78.8 Lakh ₹1.42 Cr
Depreciation & Amortisation ₹30.74 Cr ₹27.99 Cr ₹13.44 Cr ₹12.36 Cr ₹12.15 Cr
Other Expenses ₹90.02 Cr ₹71 Cr ₹69.15 Cr ₹57.09 Cr ₹47.28 Cr
Total Expenses ₹834.92 Cr ₹698.14 Cr ₹567.33 Cr ₹466.01 Cr ₹427.07 Cr
Profit Before Exceptional Items & Tax ₹86.98 Cr ₹79.76 Cr ₹77.09 Cr ₹57.04 Cr ₹45.57 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹86.98 Cr ₹79.76 Cr ₹77.09 Cr ₹57.04 Cr ₹45.57 Cr
Total Tax Expense ₹20.52 Cr ₹18.76 Cr ₹18.9 Cr ₹14.41 Cr ₹7.48 Cr
Net Profit ₹66.46 Cr ₹60.99 Cr ₹58.19 Cr ₹42.63 Cr ₹38.09 Cr
  attributable to Owners - ₹0 ₹0 - ₹37.9 Cr
  attributable to NCI - ₹0 ₹0 - ₹0
Other Comprehensive Income ₹11.1 Lakh -₹54.9 Lakh -₹24.8 Lakh -₹18.3 Lakh -₹18.6 Lakh
Total Comprehensive Income ₹66.57 Cr ₹60.45 Cr ₹57.94 Cr ₹42.44 Cr ₹37.9 Cr
EBITDA (computed) ₹122.55 Cr ₹112.13 Cr ₹91.64 Cr ₹70.19 Cr ₹59.13 Cr
Basic EPS ₹31.60 ₹29.19 ₹27.97 ₹19.70 ₹18.80
Diluted EPS ₹31.15 ₹28.87 ₹27.88 ₹19.70 ₹18.80
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹907.35 Cr ₹760.45 Cr ₹626.21 Cr ₹528.98 Cr
Non-current Assets ₹280.5 Cr ₹235.32 Cr ₹194.92 Cr ₹175.44 Cr
Current Assets ₹626.85 Cr ₹525.13 Cr ₹431.29 Cr ₹353.54 Cr
Property, Plant & Equipment ₹187.18 Cr ₹195.49 Cr ₹169.49 Cr ₹102.6 Cr
Inventories ₹61.82 Cr ₹81.38 Cr ₹62.19 Cr ₹74.74 Cr
Trade Receivables ₹227.4 Cr ₹166.86 Cr ₹136.28 Cr ₹116.86 Cr
Cash & Equivalents ₹53.5 Lakh ₹42.4 Lakh ₹5.29 Cr ₹3.69 Cr
Equity (Net Worth) ₹580.84 Cr ₹505.77 Cr ₹449.94 Cr ₹402.27 Cr
Equity Share Capital ₹10.55 Cr ₹10.48 Cr ₹10.4 Cr ₹10.46 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹10.9 Lakh
Borrowings (Current) ₹29.88 Cr ₹27.12 Cr ₹10.9 Lakh ₹33.5 Lakh
Total Debt (computed) ₹29.88 Cr ₹27.12 Cr ₹10.9 Lakh ₹44.4 Lakh
Current Liabilities ₹320.93 Cr ₹249.44 Cr ₹171.75 Cr ₹121.24 Cr
Total Liabilities ₹326.51 Cr ₹254.68 Cr ₹176.27 Cr ₹126.7 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹104.93 Cr ₹68.19 Cr ₹108.96 Cr ₹60.97 Cr ₹9.13 Cr
Investing Cash Flow -₹91.79 Cr -₹74.06 Cr -₹92.07 Cr -₹14.11 Cr -₹154.58 Cr
Financing Cash Flow -₹13.03 Cr ₹1.01 Cr -₹15.29 Cr -₹43.74 Cr ₹130.09 Cr
Capital Expenditure ₹67.66 Cr ₹52.19 Cr ₹37.68 Cr ₹70.89 Cr ₹14.8 Cr
Free Cash Flow (computed) ₹37.27 Cr ₹15.99 Cr ₹71.28 Cr -₹9.93 Cr -₹5.67 Cr
Dividends Paid ₹12.16 Cr ₹11.5 Cr ₹8.3 Cr ₹7.63 Cr ₹0
Net Change in Cash ₹11.1 Lakh -₹4.86 Cr ₹1.6 Cr ₹3.12 Cr -₹15.36 Cr
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹238.5 Cr ₹233.1 Cr ₹222.4 Cr ₹210.09 Cr ₹202.71 Cr ₹195.02 Cr ₹187 Cr ₹175.15 Cr ₹171.29 Cr ₹162.21 Cr ₹152.67 Cr ₹144.79 Cr
Other Income ₹4.35 Cr ₹4.57 Cr ₹3.65 Cr ₹5.24 Cr ₹4.94 Cr ₹4.11 Cr ₹4.84 Cr ₹4.13 Cr ₹4.44 Cr ₹3.16 Cr ₹3.24 Cr ₹2.62 Cr
Total Income ₹242.85 Cr ₹237.67 Cr ₹226.04 Cr ₹215.33 Cr ₹207.64 Cr ₹199.13 Cr ₹191.84 Cr ₹179.29 Cr ₹175.73 Cr ₹165.38 Cr ₹155.91 Cr ₹147.41 Cr
Cost of Materials Consumed ₹3.78 Cr -₹5.47 Cr ₹8.04 Cr ₹6.11 Cr ₹3.33 Cr ₹87.7 Lakh ₹37.7 Lakh -₹2.26 Cr ₹2.06 Cr -₹5.43 Cr ₹4.35 Cr ₹1.98 Cr
Purchases of Stock-in-Trade ₹141.68 Cr ₹140.4 Cr ₹136.25 Cr ₹119.35 Cr ₹111.77 Cr ₹133.64 Cr ₹127.17 Cr ₹118.48 Cr ₹104.55 Cr ₹105.34 Cr ₹86.45 Cr ₹87.29 Cr
Changes in Inventories ₹1.59 Cr ₹8.58 Cr -₹7.34 Cr ₹4.28 Cr ₹10.1 Cr -₹13.68 Cr -₹11.12 Cr -₹6.82 Cr ₹54.7 Lakh ₹1.73 Cr ₹5.08 Cr ₹2.24 Cr
Employee Benefit Expense ₹41.37 Cr ₹42.05 Cr ₹36.45 Cr ₹32.23 Cr ₹31.93 Cr ₹32.17 Cr ₹30.97 Cr ₹27.85 Cr ₹22.85 Cr ₹22.73 Cr ₹21.32 Cr ₹20.56 Cr
Finance Costs ₹1.48 Cr ₹1.28 Cr ₹1.02 Cr ₹1.06 Cr ₹1.33 Cr ₹1.46 Cr ₹1.1 Cr ₹49.2 Lakh ₹27.7 Lakh ₹30.5 Lakh ₹28.5 Lakh ₹23.8 Lakh
Depreciation & Amortisation ₹8 Cr ₹7.7 Cr ₹7.6 Cr ₹7.45 Cr ₹8.34 Cr ₹6.94 Cr ₹6.5 Cr ₹6.21 Cr ₹3.54 Cr ₹3.39 Cr ₹3.33 Cr ₹3.19 Cr
Other Expenses ₹24.79 Cr ₹23.18 Cr ₹20.45 Cr ₹21.61 Cr ₹20.04 Cr ₹17.39 Cr ₹16.56 Cr ₹17.02 Cr ₹19.28 Cr ₹17.5 Cr ₹16.8 Cr ₹15.58 Cr
Total Expenses ₹222.69 Cr ₹217.7 Cr ₹202.46 Cr ₹192.07 Cr ₹186.82 Cr ₹178.79 Cr ₹171.56 Cr ₹160.98 Cr ₹153.09 Cr ₹145.57 Cr ₹137.6 Cr ₹131.07 Cr
Profit Before Exceptional Items & Tax ₹20.16 Cr ₹19.97 Cr ₹23.59 Cr ₹23.26 Cr ₹20.82 Cr ₹20.34 Cr ₹20.29 Cr ₹18.31 Cr ₹22.63 Cr ₹19.81 Cr ₹18.31 Cr ₹16.34 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹20.16 Cr ₹19.97 Cr ₹23.59 Cr ₹23.26 Cr ₹20.82 Cr ₹20.34 Cr ₹20.29 Cr ₹18.31 Cr ₹22.63 Cr ₹19.81 Cr ₹18.31 Cr ₹16.34 Cr
Total Tax Expense ₹4.17 Cr ₹4.97 Cr ₹5.79 Cr ₹5.59 Cr ₹4.54 Cr ₹4.76 Cr ₹4.63 Cr ₹4.83 Cr ₹5.64 Cr ₹4.71 Cr ₹4.28 Cr ₹4.28 Cr
Net Profit ₹15.99 Cr ₹15 Cr ₹17.8 Cr ₹17.66 Cr ₹16.28 Cr ₹15.58 Cr ₹15.66 Cr ₹13.48 Cr ₹16.99 Cr ₹15.1 Cr ₹14.03 Cr ₹12.07 Cr
  attributable to Owners - ₹0 - ₹0 ₹0 ₹0 ₹0 - ₹0 ₹15.1 Cr - -
  attributable to NCI - ₹0 - ₹0 ₹0 ₹0 ₹0 - ₹0 ₹0 - -
Other Comprehensive Income ₹7.9 Lakh ₹17.3 Lakh -₹17.6 Lakh ₹3.6 Lakh ₹15.9 Lakh -₹2.1 Lakh -₹22.3 Lakh -₹46.4 Lakh ₹3.5 Lakh ₹2.6 Lakh ₹1.9 Lakh -₹32.8 Lakh
Total Comprehensive Income ₹16.07 Cr ₹15.18 Cr ₹17.62 Cr ₹17.7 Cr ₹16.44 Cr ₹15.56 Cr ₹15.44 Cr ₹13.02 Cr ₹17.03 Cr ₹15.12 Cr ₹14.05 Cr ₹11.74 Cr
EBITDA (computed) ₹29.64 Cr ₹28.95 Cr ₹32.2 Cr ₹31.76 Cr ₹30.49 Cr ₹28.74 Cr ₹27.89 Cr ₹25.01 Cr ₹26.45 Cr ₹23.5 Cr ₹21.93 Cr ₹19.77 Cr
Basic EPS ₹7.58 ₹7.12 ₹8.48 ₹8.43 ₹7.77 ₹7.45 ₹7.49 ₹6.47 ₹8.17 ₹7.26 ₹6.75 ₹5.79
Diluted EPS ₹7.49 ₹7.05 ₹8.40 ₹8.34 ₹7.69 ₹7.38 ₹7.43 ₹6.44 ₹8.14 ₹7.26 ₹6.75 ₹5.79
Latest 12 quarters shown of 20 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Revenue from Operations ₹904.09 Cr ₹759.88 Cr ₹630.96 Cr ₹513.08 Cr ₹465.93 Cr
Other Income ₹17.8 Cr ₹17.65 Cr ₹13.47 Cr ₹9.97 Cr ₹6.71 Cr
Total Income ₹921.89 Cr ₹777.52 Cr ₹644.42 Cr ₹523.05 Cr ₹472.64 Cr
Cost of Materials Consumed ₹12.46 Cr ₹2.33 Cr ₹2.96 Cr -₹76.2 Lakh ₹307.56 Cr
Purchases of Stock-in-Trade ₹537.67 Cr ₹491.05 Cr ₹383.63 Cr ₹341.48 Cr ₹0
Changes in Inventories ₹7.1 Cr -₹21.52 Cr ₹9.59 Cr -₹15.27 Cr -₹4.74 Cr
Employee Benefit Expense ₹152.09 Cr ₹122.92 Cr ₹87.46 Cr ₹70.32 Cr ₹63.41 Cr
Finance Costs ₹4.83 Cr ₹4.38 Cr ₹1.1 Cr ₹78.6 Lakh ₹1.42 Cr
Depreciation & Amortisation ₹30.74 Cr ₹27.99 Cr ₹13.44 Cr ₹12.36 Cr ₹12.15 Cr
Other Expenses ₹90.07 Cr ₹70.99 Cr ₹69.22 Cr ₹57.07 Cr ₹46.81 Cr
Total Expenses ₹834.96 Cr ₹698.13 Cr ₹567.4 Cr ₹465.99 Cr ₹426.6 Cr
Profit Before Exceptional Items & Tax ₹86.93 Cr ₹79.39 Cr ₹77.02 Cr ₹57.06 Cr ₹46.04 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹86.93 Cr ₹79.39 Cr ₹77.02 Cr ₹57.06 Cr ₹46.04 Cr
Total Tax Expense ₹20.5 Cr ₹18.75 Cr ₹18.88 Cr ₹14.41 Cr ₹7.48 Cr
Net Profit ₹66.44 Cr ₹60.65 Cr ₹58.14 Cr ₹42.64 Cr ₹38.56 Cr
Other Comprehensive Income ₹11.1 Lakh -₹54.3 Lakh -₹24.3 Lakh -₹15.6 Lakh -₹18 Lakh
Total Comprehensive Income ₹66.55 Cr ₹60.11 Cr ₹57.9 Cr ₹42.49 Cr ₹38.38 Cr
EBITDA (computed) ₹122.5 Cr ₹111.76 Cr ₹91.57 Cr ₹70.21 Cr ₹59.6 Cr
Basic EPS ₹31.59 ₹29.03 ₹27.95 ₹19.71 ₹18.81
Diluted EPS ₹31.14 ₹28.71 ₹27.86 ₹19.71 ₹18.81
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹907.34 Cr ₹760.45 Cr ₹626.16 Cr ₹529.01 Cr
Non-current Assets ₹280.5 Cr ₹235.32 Cr ₹194.92 Cr ₹175.47 Cr
Current Assets ₹626.84 Cr ₹525.13 Cr ₹431.24 Cr ₹353.54 Cr
Property, Plant & Equipment ₹187.18 Cr ₹195.49 Cr ₹169.49 Cr ₹102.6 Cr
Inventories ₹61.82 Cr ₹81.38 Cr ₹62.19 Cr ₹74.74 Cr
Trade Receivables ₹227.4 Cr ₹166.86 Cr ₹136.28 Cr ₹116.86 Cr
Cash & Equivalents ₹52.6 Lakh ₹42.1 Lakh ₹5.24 Cr ₹3.69 Cr
Equity (Net Worth) ₹580.83 Cr ₹505.79 Cr ₹450.29 Cr ₹402.67 Cr
Equity Share Capital ₹10.55 Cr ₹10.48 Cr ₹10.4 Cr ₹10.46 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹10.9 Lakh
Borrowings (Current) ₹29.88 Cr ₹27.12 Cr ₹10.9 Lakh ₹33.5 Lakh
Total Debt (computed) ₹29.88 Cr ₹27.12 Cr ₹10.9 Lakh ₹44.4 Lakh
Current Liabilities ₹320.93 Cr ₹249.42 Cr ₹171.35 Cr ₹120.88 Cr
Total Liabilities ₹326.51 Cr ₹254.66 Cr ₹175.87 Cr ₹126.34 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹104.93 Cr ₹68.23 Cr ₹108.91 Cr ₹60.98 Cr ₹9 Cr
Investing Cash Flow -₹91.79 Cr -₹74.06 Cr -₹92.07 Cr -₹14.11 Cr -₹154.31 Cr
Financing Cash Flow -₹13.03 Cr ₹1.01 Cr -₹15.29 Cr -₹43.74 Cr ₹130.09 Cr
Capital Expenditure ₹67.66 Cr ₹52.19 Cr ₹37.68 Cr ₹70.89 Cr ₹14.8 Cr
Free Cash Flow (computed) ₹37.26 Cr ₹16.04 Cr ₹71.23 Cr -₹9.91 Cr -₹5.8 Cr
Dividends Paid ₹12.16 Cr ₹11.5 Cr ₹8.3 Cr ₹7.63 Cr ₹0
Net Change in Cash ₹10.5 Lakh -₹4.82 Cr ₹1.56 Cr ₹3.13 Cr -₹15.22 Cr
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹238.5 Cr ₹233.1 Cr ₹222.4 Cr ₹210.09 Cr ₹202.71 Cr ₹195.02 Cr ₹187 Cr ₹175.15 Cr ₹171.29 Cr ₹162.21 Cr ₹152.67 Cr ₹144.79 Cr
Other Income ₹4.4 Cr ₹4.52 Cr ₹3.65 Cr ₹5.24 Cr ₹4.94 Cr ₹3.73 Cr ₹4.84 Cr ₹4.13 Cr ₹4.44 Cr ₹3.16 Cr ₹3.24 Cr ₹2.62 Cr
Total Income ₹242.9 Cr ₹237.62 Cr ₹226.04 Cr ₹215.33 Cr ₹207.65 Cr ₹198.75 Cr ₹191.84 Cr ₹179.29 Cr ₹175.73 Cr ₹165.38 Cr ₹155.91 Cr ₹147.41 Cr
Cost of Materials Consumed ₹3.78 Cr -₹5.47 Cr ₹8.04 Cr ₹6.11 Cr ₹3.33 Cr ₹87.7 Lakh ₹37.7 Lakh -₹2.26 Cr ₹2.06 Cr -₹5.43 Cr ₹4.35 Cr ₹1.98 Cr
Purchases of Stock-in-Trade ₹141.68 Cr ₹140.4 Cr ₹136.25 Cr ₹119.35 Cr ₹111.77 Cr ₹133.64 Cr ₹127.17 Cr ₹118.48 Cr ₹104.55 Cr ₹105.34 Cr ₹86.45 Cr ₹87.29 Cr
Changes in Inventories ₹1.59 Cr ₹8.58 Cr -₹7.34 Cr ₹4.28 Cr ₹10.1 Cr -₹13.68 Cr -₹11.12 Cr -₹6.82 Cr ₹54.7 Lakh ₹1.73 Cr ₹5.08 Cr ₹2.24 Cr
Employee Benefit Expense ₹41.37 Cr ₹42.05 Cr ₹36.45 Cr ₹32.23 Cr ₹31.93 Cr ₹32.17 Cr ₹30.97 Cr ₹27.85 Cr ₹22.85 Cr ₹22.73 Cr ₹21.32 Cr ₹20.56 Cr
Finance Costs ₹1.48 Cr ₹1.28 Cr ₹1.02 Cr ₹1.06 Cr ₹1.33 Cr ₹1.46 Cr ₹1.1 Cr ₹49.2 Lakh ₹27.6 Lakh ₹30.5 Lakh ₹28.5 Lakh ₹23.7 Lakh
Depreciation & Amortisation ₹8 Cr ₹7.7 Cr ₹7.6 Cr ₹7.45 Cr ₹8.34 Cr ₹6.94 Cr ₹6.5 Cr ₹6.21 Cr ₹3.54 Cr ₹3.39 Cr ₹3.33 Cr ₹3.19 Cr
Other Expenses ₹24.84 Cr ₹23.18 Cr ₹20.45 Cr ₹21.61 Cr ₹20.04 Cr ₹17.38 Cr ₹16.56 Cr ₹17.02 Cr ₹19.35 Cr ₹17.5 Cr ₹16.8 Cr ₹15.58 Cr
Total Expenses ₹222.74 Cr ₹217.7 Cr ₹202.46 Cr ₹192.07 Cr ₹186.82 Cr ₹178.78 Cr ₹171.56 Cr ₹160.98 Cr ₹153.16 Cr ₹145.57 Cr ₹137.6 Cr ₹131.07 Cr
Profit Before Exceptional Items & Tax ₹20.16 Cr ₹19.92 Cr ₹23.59 Cr ₹23.26 Cr ₹20.83 Cr ₹19.97 Cr ₹20.29 Cr ₹18.31 Cr ₹22.56 Cr ₹19.81 Cr ₹18.31 Cr ₹16.34 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹20.16 Cr ₹19.92 Cr ₹23.59 Cr ₹23.26 Cr ₹20.83 Cr ₹19.97 Cr ₹20.29 Cr ₹18.31 Cr ₹22.56 Cr ₹19.81 Cr ₹18.31 Cr ₹16.34 Cr
Total Tax Expense ₹4.15 Cr ₹4.97 Cr ₹5.79 Cr ₹5.59 Cr ₹4.54 Cr ₹4.74 Cr ₹4.63 Cr ₹4.83 Cr ₹5.61 Cr ₹4.71 Cr ₹4.28 Cr ₹4.28 Cr
Net Profit ₹16.02 Cr ₹14.95 Cr ₹17.8 Cr ₹17.67 Cr ₹16.29 Cr ₹15.23 Cr ₹15.66 Cr ₹13.48 Cr ₹16.95 Cr ₹15.1 Cr ₹14.03 Cr ₹12.07 Cr
Other Comprehensive Income ₹7.7 Lakh ₹17.2 Lakh -₹17.4 Lakh ₹3.6 Lakh ₹17.5 Lakh -₹3.3 Lakh -₹22.1 Lakh -₹46.4 Lakh ₹3.6 Lakh ₹2.6 Lakh ₹2.4 Lakh -₹32.9 Lakh
Total Comprehensive Income ₹16.09 Cr ₹15.13 Cr ₹17.63 Cr ₹17.7 Cr ₹16.46 Cr ₹15.19 Cr ₹15.44 Cr ₹13.02 Cr ₹16.99 Cr ₹15.12 Cr ₹14.06 Cr ₹11.74 Cr
EBITDA (computed) ₹29.64 Cr ₹28.9 Cr ₹32.2 Cr ₹31.76 Cr ₹30.49 Cr ₹28.37 Cr ₹27.89 Cr ₹25.01 Cr ₹26.38 Cr ₹23.5 Cr ₹21.93 Cr ₹19.77 Cr
Basic EPS ₹7.60 ₹7.09 ₹8.48 ₹8.43 ₹7.77 ₹7.29 ₹7.49 ₹6.47 ₹8.15 ₹7.26 ₹6.75 ₹5.79
Diluted EPS ₹7.50 ₹7.03 ₹8.40 ₹8.34 ₹7.69 ₹7.21 ₹7.43 ₹6.44 ₹8.12 ₹7.26 ₹6.75 ₹5.79
Latest 12 quarters shown of 19 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Windlas Biotech Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Windlas Biotech Limited

As per the shareholding pattern filed with NSE for the quarter ended May 2026, promoters hold 63.31%, foreign institutional investors hold 0.99%, domestic institutional investors hold 10.20%, retail and other public shareholders hold 25.50% of Windlas Biotech Limited. The company had 46,084 shareholders on record.

Promoters: 63.31%DII (Domestic Institutional): 10.20%FII (Foreign Institutional): 0.99%Retail & Others: 25.50%
May 2026
QUARTER
63.31% Promoters
10.20% DII (Domestic Institutional)
0.99% FII (Foreign Institutional)
25.50% Retail & Others
Promoter holding - history
Now 63.31% · May 2026High 63.31% · May 2026Low 59.95% · Aug 2021
58%59.8%61.5%63.3%65%Aug 2021Sep 2022Jun 2023Sep 2024Dec 2025Aug 2021: 59.95%Sep 2021: 59.95%Dec 2021: 59.95%Mar 2022: 59.95%Jun 2022: 59.95%Sep 2022: 59.95%Dec 2022: 60.75%Feb 2023: 61.22%Mar 2023: 62.38%Apr 2023: 62.44%Jun 2023: 62.82%Sep 2023: 62.82%Dec 2023: 62.82%Mar 2024: 62.82%Jun 2024: 62.51%Sep 2024: 62.51%Dec 2024: 62.51%Mar 2025: 62.34%Jun 2025: 62.34%Sep 2025: 61.99%Dec 2025: 61.99%Mar 2026: 61.90%May 2026: 63.31%59.95%63.31%
Shareholding trend - last 6 quarters
May 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025
Promoters63.31%61.90%61.99%61.99%62.34%62.34%
Public36.69%38.10%38.01%38.01%37.66%37.66%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Promoters61.90%62.34%62.82%62.38%59.95%
Public38.10%37.66%37.18%37.62%40.05%
Promoter change (YoY, %pts)-0.44-0.48+0.44+2.43-

Board & Governance of Windlas Biotech Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Windlas Biotech Limited has 8 directors - 3 independent and 4 executive. The board is chaired by VIVEK DHARIWAL.

DirectorPositionOn board sinceListed boards
VIVEK DHARIWAL Non-Executive - Independent Director · Chairperson 2021-05-06 1
ASHOK KUMAR WINDLASS Executive Director 2001-02-19 1
HITESH WINDLASS Executive Director 2008-01-21 1
MANOJ KUMAR WINDLASS Executive Director 2006-04-01 1
PAWAN KUMAR SHARMA Executive Director 2019-06-11 1
GAURAV GULATI Non-Executive - Independent Director 2021-05-06 1
PRACHI JAIN WINDLASS Non-Executive - Non Independent Director 2021-05-03 1
SRINIVASAN VENKATARAMAN Non-Executive - Independent Director 2021-05-06 1
Board Committees
CommitteeMembers
Audit Committee SRINIVASAN VENKATARAMAN (Chairperson), GAURAV GULATI, HITESH WINDLASS
Nomination and remuneration committee SRINIVASAN VENKATARAMAN (Chairperson), VIVEK DHARIWAL, GAURAV GULATI
Stakeholders Relationship Committee GAURAV GULATI (Chairperson), PRACHI JAIN WINDLASS, MANOJ KUMAR WINDLASS

Charges & Borrowings of Windlas Biotech Limited

Open charges
₹73.3 Cr
Satisfied charges
₹183.4 Cr
Breakdown by lending institutions
The Hongkong and Shanghai Banking Corporation Limited₹40.00 Cr
Hdfc Bank Limited₹23.30 Cr
Others₹10.00 Cr
Latest charge details
DateLenderAmountStatus
27 May 2022 The Hongkong and Shanghai Banking Corporation Limited ₹40 Cr Open
04 Feb 2015 Others ₹10 Cr Open
28 Apr 2010 Hdfc Bank Limited ₹23.3 Cr Open
16 Apr 2021 Others ₹20 Cr Satisfied
16 Mar 2021 Others ₹20 Cr Satisfied

Total charge records: 29 View all charges

Employees and EPFO Compliance at Windlas Biotech Limited

Windlas Biotech Limited has a workforce of 1,153 employees as of Feb 18, 2026.

Employee count
1,153
Active EPFO establishments
1
Employee growth
8.57%
Premium access

Employee and EPFO history for Windlas Biotech Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Windlas Biotech Limited

Premium access

GST registrations and filing compliance for Windlas Biotech Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Windlas Biotech Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Windlas Biotech Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Windlas Biotech Limited

Premium access

MSME payment history for Windlas Biotech Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Windlas Biotech Limited

Premium access

Corporate group structure for Windlas Biotech Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Windlas Biotech Limited

Premium access

MCA filings and documents for Windlas Biotech Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Windlas Biotech Limited

Directors
05 May 2026
Tarashree Singhal was appointed as a Additional Director on 05 May 2026 & has been associated with this company since 3 months 14 days.
Activity
28 Jul 2025
Windlas Biotech Limited last Annual general meeting of members was held on 28 Jul 2025 as per latest MCA records.
Activity
31 Mar 2025
Windlas Biotech Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Uttarakhand.
Charges
20 Mar 2025
A charge registered on 13 Jul 2020 via Charge ID 100360093 with Sidbi was fully satisfied on 20 Mar 2025.
Charges
17 Mar 2025
A charge with The Hongkong And Shanghai Banking Corporation Limited of Rs. 40.00 Cr registered on 27 May 2022 with Charge ID 100575416 was modified on 17 Mar 2025.
Charges
08 Jan 2025
A charge with Hdfc Bank Limited of Rs. 23.30 Cr registered on 28 Apr 2010 with Charge ID 10223457 was modified on 08 Jan 2025.

Recent News on Windlas Biotech Limited

Tano to invest in drugmaker Windlas
28 Aug 2015 · VCCircle

Frequently Asked Questions about Windlas Biotech Limited

Windlas Biotech Limited is an active public limited company in the pharma sector based in Dehradun, Uttarakhand, India. It was incorporated on 19 February 2001 (25+ years old) and is registered under CIN L74899UR2001PLC033407. Listed on BSE: 543329 and NSE: WINDLAS. The company has 1,153 employees.

Windlas Biotech Limited reported revenue of ₹904.09 Cr for FY 2026 (up 18.98% YoY) based on consolidated NSE filings.

The current directors of Windlas Biotech Limited are:

The primary industry of Windlas Biotech Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Windlas Biotech Limited is listed on both BSE (code: 543329) and NSE (symbol: WINDLAS).

Windlas Biotech Limited can be reached at the registered office: 401 Mohabewala Industrial Area, Dehradun, Uttarakhand, India – 248110, or through the website windlas.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available